Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceutical Chemicals
Evonik will make Alzheimer’s drug candidate for Cassava
by Michael McCoy
March 12, 2021
| A version of this story appeared in
Volume 99, Issue 9
Credit: Evonik Industries
Evonik acquired the Lafayette, Indiana, facility from Eli Lilly and Company in 2010.
Evonik Industries has signed an agreement to produce clinical-grade supplies of simufilam, a developmental Alzheimer’s disease treatment, for the biotech firm Cassava Sciences. Cassava says it is talking with the US Food and Drug Administration about beginning Phase 3 studies of simufilam later this year. Evonik will produce the small molecule at its facility in Lafayette, Indiana.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X